NCT02978482 is a Phase 1 clinical trial of durvalumab in Advanced Malignancy, sponsored by AstraZeneca.

Who is sponsoring NCT02978482?

NCT02978482 is sponsored by AstraZeneca.

What drugs are being tested in NCT02978482?

Interventions in NCT02978482: durvalumab, tremelimumab + durvalumab.

What condition does NCT02978482 study?

NCT02978482 studies Advanced Malignancy.

Is NCT02978482 still recruiting?

NCT02978482 is currently completed. Last updated 18 August 2021.

Last reviewed 2021-08-18 · How we verify

NCT02978482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Completed Phase 1 Last updated 18 August 2021

What this trial tests

Phase 1 trial testing durvalumab in Advanced Malignancy in 26 participants. Completed in 26 November 2020.

Timeline

1 December 2016

Primary endpoint
28 January 2018

26 November 2020

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	1 December 2016
Primary completion	28 January 2018
Estimated completion	26 November 2020
Sites	2 locations across China

Drugs / interventions tested

durvalumab — full drug profile →
tremelimumab + durvalumab — full drug profile →

Conditions studied

Advanced Malignancy — all drugs for Advanced Malignancy →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Advanced Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in combination with tremelimumab in Chinese Patients with Advanced Malignancies

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Liu SY, Wu YL. · · 2017 · cited 38× · PMID 28679395 · DOI 10.1186/s13045-017-0506-z
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.
Ji Z, Peng Z, Gong J, Zhang X, et al · · 2019 · cited 30× · PMID 31315610 · DOI 10.1186/s12885-019-5921-9
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
Implications of Immunotherapy in Hepatobiliary Tumors.
Gottlieb A, Best J, Canbay A. · · 2019 · cited 4× · PMID 31312646 · DOI 10.1159/000496755
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
Fang W, Zhao S, Zhang Y, Ma Y, et al · · 2019 · cited 3× · PMID 30819827 · DOI 10.1634/theoncologist.2019-io-s1-s03

Verify or expand the search:

Other trials of durvalumab

Trials testing the same drug.

NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting
NCT05924880 — A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatm · Phase 3 · completed
NCT05683977 — A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Ce · active not recruiting
NCT05298423 — Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizuma · Phase 3 · active not recruiting
NCT05043090 — Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced · Phase 3 · active not recruiting

Other recruiting trials for Advanced Malignancy

Currently open trials in the same condition.

NCT07238075 — ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02978482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 18 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02978482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing